David DeRemer
@DavidDeRemer
Followers
396
Following
2K
Media
48
Statuses
1K
RT @CRC_AACR: Recently published:. Racial Disparities in Analgesic and Psychiatric Medication Use during End-of-Life Care in Advanced-Stage….
0
2
0
RT @ArndtVogel: HER2 testing: evolution and update for a companion diagnostic assay.@NatRevClinOncol .👉Accurate & p….
0
16
0
0
166
0
RT @DrYukselUrun: Time to rethink cancer trials. 🧬 Precision oncology demands:.-Early molecular profiling.-Flexible evidence (Phase 1/2, re….
0
45
0
RT @JAMA_current: Microbes in the gut and other body locations can influence cancer development, progression, and response to treatment.….
0
83
0
RT @Dr_ElvinaA: NCCN 2025 Gastric Cancer Guidelines are out!. HER2, PD-L1, CLDN18.2, MSI/MMR testing standard for advanced disease. Immunot….
0
36
0
RT @VincentRK: We call for a paradigm shift in development of immunotherapy drugs, especially bispecifics. @LeukemiaJnl . These drugs have….
0
33
0
RT @PTarantinoMD: Our @CD_AACR review article on “40 years of ADCs” will be open access during #AACR25. Great for getting up to speed and p….
0
20
0
RT @Erman_Akkus: 🔬Designing clinical trials for rare cancers.@ASCO . ✅Innovative designs.✅Precision med and NGS.✅Tumor-agnıstic therapies.✅….
0
12
0
RT @PTarantinoMD: Evolution of HER2 testing over 40 yrs. IHC lacks the dynamic range to predict outcomes with T-DXd, yet novel quantitativ….
0
68
0
RT @Erman_Akkus: 🛰️SPACE-FLOT full article published.@BJSurgery . ❓Neoadjuvant FLOT, surgery, then adjuvant FLOT all comers? pathological r….
0
52
0
RT @jasonlukemd: A @sitcancer vision statement on accelerating #clinicaltrials to get 100 immunotherapy regulatory approvals in 10 years. E….
0
13
0
RT @ArndtVogel: Concordance of ctDNA & tissue genomic profiling in advanced BTC.@JHepatology .🔎RWD.👉85% concordance….
0
17
0
RT @PTarantinoMD: Very nice review on HER3 targeting by Helena Yu and colleagues. A bispecific HER3xHER2 mAb was recently approved in thora….
0
30
0
RT @Annals_Oncology: 🆕review article in press: Efficacy assessment in phase I clinical trials: endpoints and challenges @mgoudaMD, @Garrido….
0
12
0
RT @jitcancer: New #JITC article: Tumor mutational burden and survival on immune checkpoint inhibition in >8000 patients across 24 cancer t….
0
4
0
RT @ESMO_Open: New on @ESMO_Open: A group of 36 pathologists re-evaluated 50 HER2 IHC slides that had been previously diagnosed as HER2 0.….
0
19
0